Apixaban for treatment of embolic stroke of undetermined source (ATTICUS randomized trial): Rationale and study design
Abstract
Rationale Optimal secondary prevention of embolic stroke of undetermined source is not established. The current standard in these patients is acetylsalicylic acid, despite high prevalence of yet undetected paroxysmal atrial fibrillation. Aim The ATTICUS randomized trial is designed to determine whether the factor Xa inhibitor apixaban administered within 7 days after embolic stroke of undetermined source, is superior to acetylsalicylic acid for...
Paper Details
Title
Apixaban for treatment of embolic stroke of undetermined source (ATTICUS randomized trial): Rationale and study design
Published Date
Nov 23, 2016
Volume
12
Issue
9
Pages
985 - 990
Citation AnalysisPro
You’ll need to upgrade your plan to Pro
Looking to understand the true influence of a researcher’s work across journals & affiliations?
- Scinapse’s Top 10 Citation Journals & Affiliations graph reveals the quality and authenticity of citations received by a paper.
- Discover whether citations have been inflated due to self-citations, or if citations include institutional bias.
Notes
History